📌 Key Takeaways
- ECM (Extracellular Matrix) injectables are primarily manufactured from decellularized cadaver skin tissue, marketed as “5th generation” aesthetic injectables. Products like BNAJU (Elravie Re2O), Skinplus (CellREDM), and JUVEACELL (ESSALIA) are expanding rapidly across Korea, Japan, and Singapore
- Korea’s MFDS (Ministry of Food and Drug Safety) announced regulatory action in H1 2026 following a National Assembly forum (April 16, 2026) that identified four critical issues: absence of clinical trials, no SDS residue standards, technical contradictions in decellularization, and ethical concerns over donor intent
- While manufacturers cite rigorous sterility protocols and US AATB certification, critical information gaps persist—including the absence of international standards for SDS residue in subcutaneous injection and limited clinical trial scale—creating structural “information asymmetry” between providers and consumers. Note: Cadaver-derived and placenta-derived materials are fundamentally different sources and must not be conflated
“Do you know what this ECM injection is made from?”
Few patients receiving aesthetic treatments at clinics are ever asked this question during consultation.
Yet in April–May 2026, this question triggered significant controversy across Korea’s National Assembly, MFDS (the Korean equivalent of Japan’s PMDA), and medical community.
What Are ECM (Extracellular Matrix) Injectables?
ECM stands for Extracellular Matrix—the structural scaffold between cells composed of collagen, elastin, hyaluronic acid, fibronectin, and other proteins. As we age, ECM degrades and diminishes, leading to loss of skin firmness, elasticity, and moisture retention. ECM skin boosters are based on the concept of “external supplementation” of this matrix.
📊 Injectable “Generations” Map
Hyaluronic Acid (Restylane, Juvederm)—hydration, volume, wrinkle correction
PDRN/PN (Rejuran)—salmon DNA-derived collagen stimulation
Biostimulators (PLLA, CaHA)—collagen fiber remodeling
Exosomes—intercellular signaling and regeneration
ECM Injectables (today’s focus)—decellularized cadaver tissue for dermal matrix reconstruction
Manufacturing Process: The Complete Picture
🔬 ECM Skin Booster Manufacturing Process (hADM: Human Acellular Dermal Matrix)
① Tissue Procurement: Skin tissue harvested from consenting cadaver donors. According to Korea’s Ministry of Health and Welfare, current products use imported materials (primarily from US AATB-certified tissue banks); Korean domestic donors are not used
② Decellularization: Freeze-drying, pulverization, chemical treatment. SDS (Sodium Dodecyl Sulfate—a powerful surfactant also found in toothpaste and detergents) and other chemicals dissolve cell membranes, leaving only ECM components like collagen
③ Powder Formation & Formulation: Processed ECM components are powdered (hADM powder) and formulated into injectable products
④ Clinical Injection: Physicians inject into dermis/subcutaneous tissue to promote collagen production and dermal matrix reconstruction
Four Critical Issues Confirmed by Korean Authorities
Between March and May 2026, multiple Korean government agencies formally addressed this issue.
📅 Korean Government Action Timeline (2026)
Feb 24
MFDS and Ministry of Health initiate regulatory necessity research
Mar 30
MFDS officially classifies ECM skin boosters as “human tissue material (not medical device)” while simultaneously “announcing regulatory action including legal amendments within H1 2026” (Edaily report, March 30)
Apr 16
National Assembly Member Seo Young-seok hosts “15th K-Bio Health Forum” (National Assembly Building) formally debating the issue
May 27
Health Kyunghyang publishes detailed safety investigation titled “Is My Skin a Guinea Pig?”
⚠️ Four Issues Confirmed by Authorities & Experts
Issue ① No Clinical Trials—Safety Claims Based on 20-Person Studies
ECM skin boosters are classified as “tissue transplant materials” in Korea, allowing market distribution without the clinical trials and product approval required for pharmaceuticals/medical devices. Some products claim safety based on trials involving merely 20 participants—medically insufficient evidence according to experts.
Issue ② SDS (Detergent Component) Residue—Zero Regulatory Standards
SDS used in decellularization binds strongly to tissue proteins, making complete removal technically impossible. Furthermore, “permissible SDS residue standards for subcutaneous injection” do not exist globally. Experts warn of risks including severe immune rejection, chronic inflammation, and worst-case tissue necrosis (Health Kyunghyang, May 27, 2026).
Issue ③ “Decellularization Paradox”—Structure Preservation vs. Cell Removal Cannot Coexist
Preserving ECM active components (collagen, etc.) while completely removing immune-triggering cells and DNA is fundamentally impossible with current technology. Complete removal destroys ECM structure; preserving structure leaves cellular components—a growing number of experts point to this inherent contradiction.
Issue ④ Deviation from Donor Intent—Ethical Concerns
Organ and tissue donation is conducted for “therapeutic and public benefit” purposes. Strong criticism exists regarding commercial aesthetic use (wrinkle reduction, skin improvement). Professor Lee Dong-han’s survey (Sookmyung Women’s University, 1,034 respondents) found 60.9% support “prohibition or strict regulation” of human tissue for aesthetic purposes. A separate consumer group survey found approximately 70% express “aversion to cadaver-derived skin booster treatments”.
MFDS Regulatory Direction
Korea’s MFDS (Ministry of Food and Drug Safety—combining functions similar to Japan’s PMDA and MHLW) issued an official position on March 30, 2026.
MFDS Official, March 30, 2026 (Edaily report)
📊 Consumer Surveys—”Aversion” to ECM Products (Korea, Multiple Studies)
Two key points emerge from this announcement:
Two Key Points from MFDS Announcement
- Current Classification: ECM skin boosters classified as “tissue transplant materials” (not medical devices)—for manufacturers, this eliminates immediate sales suspension risk
- However, Regulation Announced: “Due to divergent interpretations and opinions on aesthetic use of human tissue, we will implement regulation including legal amendments within H1 2026.” Advertising restrictions for aesthetic purposes and limitations on procedures outside comprehensive hospitals are under consideration
“Informed Consent”—The Reality of Uninformed Injections
The National Assembly forum most critically addressed “insufficient patient information disclosure.”
“Patient consent based on adequate information.” A fundamental principle of medical ethics requiring patients to understand treatment content, risks, and alternatives before voluntarily consenting. The ECM product issue is that only marketing language like “human-derived safety” and “cutting-edge skin regeneration” reaches patients, while essential information—”tissue harvested from cadavers,” “detergent chemical processing,” “clinical trial scale”—does not.
① “What is the source material for this product? Is it cadaver-derived?”
If cadaver (deceased donor) origin is not explicitly explained, this is problematic. Note: “Placenta-derived” and “cadaver-derived” are completely different sources—placenta is harvested from living donors during childbirth; avoid conflation.② “What is the scale of clinical trial data?”
20-person trials are insufficient evidence for long-term safety. Confirm whether large-scale clinical trials were conducted.③ “Are chemicals like SDS used in manufacturing? What are residue standards?”
Confirm with awareness that global residue standards currently do not exist.④ “What evidence supports this product’s safety?”
Depending on product classification, ECM products may or may not fall under regenerative medicine law notification requirements (some are processed as fully decellularized protein materials). Rather than asking about notification status, it’s crucial to confirm “what evidence the treating physician uses to verify safety and explain to patients.”
“Cadaver-Derived Hormones” Once Existed—Lessons from Medical History
Here we pose a fundamental question:
“What about insulin and growth hormone? Hormone medications are also injected into the body—weren’t they cadaver-derived?”
A sharp question. And understanding its answer reveals why the current ECM product controversy shakes the medical community so profoundly.
Currently, most insulin, growth hormone, and fertility hormones used clinically are manufactured through recombinant DNA technology. Bacteria or yeast cells are genetically engineered with “human hormone-producing genes” to safely synthesize hormones at industrial scale. Some placenta products are “human-derived,” but from placentas at childbirth—safely harvested from living donors. In modern medicine, the practice of “injecting extracts from cadaver tissue into others’ bodies” has been virtually eliminated. But it was once different. And that history directly connects to today’s ECM issue.
1960–1985: Cadaver Pituitary Growth Hormone Killed Children
From the 1960s to early 1980s, the US treated children with growth disorders using growth hormone (chGH: cadaveric human Growth Hormone) extracted from cadaver “pituitary glands”—small hormone-secreting tissues at the brain’s base.
Approximately 7,700 US patients received this treatment (CDC, Emerging Infectious Diseases 2025).
Then in 1985, tragedy emerged.
📜 Cadaveric Growth Hormone (chGH) Tragedy Timeline (CDC & Peer-Reviewed Journals)
1960s~
US begins administering cadaver pituitary-derived growth hormone (chGH) to children with growth disorders. Approximately 7,700 patients worldwide (US) received treatment
1985
FDA emergency halt. Multiple treated patients developed Creutzfeldt-Jakob Disease (CJD), a fatal brain disease
Cause
“Prions” (abnormal proteins) lurking in cadavers bypassed manufacturing processes and entered bodies via injection. Prions cannot be completely inactivated by standard sterilization (heat, chemical treatment)
Up to 48 years
Incubation period: 5–42 years (average 17 years). In 2025, a woman who received treatment from age 7 died an estimated 48 years later (CDC Emerging Infectious Diseases). Over 226 iatrogenic CJD deaths confirmed globally
“Infectious abnormal proteins” formed when normal proteins misfold. Unlike viruses or bacteria, prions contain no DNA or RNA. They cause Mad Cow Disease (BSE) and Creutzfeldt-Jakob Disease (CJD). Their most terrifying characteristic: “standard sterilization doesn’t work.” Heat, radiation, and most chemicals cannot inactivate them, meaning “decellularization ensures safety” cannot be guaranteed in all cases.
What This History Means for ECM Products
After this tragedy, the medical community learned a painful lesson: “injecting or administering cadaver tissue into others’ bodies carries unknown infectious disease risks (including prions).” This is the primary reason hormones shifted to recombinant technology.
Reading current ECM product issues through this lens reveals their severity.
⚖️ Past Tragedy vs. Current ECM Products—Similarities and Differences
Past (Cadaver Growth Hormone)
- Source: Cadaver pituitary tissue
- Purpose: Life-threatening disease treatment
- Clinical trials: Conducted (by era’s standards)
- Result: 226+ deaths from prion contamination
Present (ECM Skin Boosters)
- Source: Cadaver skin tissue (hADM)
- Purpose: Aesthetics (wrinkles, skin quality)
- Clinical trials: 20-person scale
- SDS residue standards: None
Medical Community’s Primary Concern: Previously, “used despite risks to save lives.” Now, “imposing equivalent or greater risks on consumers for non-life-threatening aesthetic purposes”—this structural difference
Impact on Japanese Market—”Information Disclosure and Consent Quality” Under Question
In Japan’s market, latest-generation ECM products based on hADM (Human Acellular Dermal Matrix) have been introduced at select clinics. Manufacturers emphasize safety based on advanced sterility management and US AATB certification, and introducing clinics provide treatments under physician discretion based on manufacturer explanations.
However, multifaceted information that Korea’s National Assembly and MFDS have officially begun debating—”absence of international standards for SDS residue in subcutaneous injection,” “clinical trial scale,” “ethical questions about off-purpose donor use”—may not sufficiently reach Japanese consumers and practicing physicians. This represents a structural problem of “information asymmetry.”
L&C Bio, manufacturer of Re2O (BNAJU), held a press conference in Seoul on April 29, 2026, directly rebutting the controversy. CEO Lee Hwan-chul stated: “The expression ‘injecting cadaver skin into faces’ is a distorted frame born from provocative language and misunderstanding, not scientific fact.” He positioned Re2O as “regenerative medicine technology based on human tissue, not simple cosmetic injection,” citing US AATB certification and rigorous sterility protocols as safety evidence. NERO’s position is to equally convey both manufacturer claims and official agency/expert concerns. This controversy is ongoing, with final judgment dependent on accumulating scientific evidence and regulatory authority decisions.
📊 Korean Regulatory Developments’ Predicted Impact on Japanese Market
NERO has previously covered Skinplus and BNAJU as “next-generation skin regeneration ingredients.” That coverage was premised on manufacturer-presented “cutting-edge design philosophy.” But overlaying current government agency actions with medical history lessons, we must honestly convey something: In 1985, cadaver-derived growth hormone contaminated with prions (abnormal proteins) caused children to develop fatal brain disease. Learning from that tragedy, the medical community recognized “dangers of injecting cadaver tissue into others’ bodies” and shifted to recombinant technology. Researchers and regulators familiar with this history view the current ECM product boom with strong discomfort: “Why are we reviving that dangerous approach now, for aesthetic purposes?” Previously, “used despite risks to save lives.” Now, “imposing equivalent or greater risks on consumers for non-life-threatening aesthetic purposes”—this structural asymmetry is the issue’s core. NERO does not oppose specific products or clinics introducing them. Medical choices should always occur under physician discretion and patient consent. However, disclosing not only cutting-edge trends’ “light” but equally the “shadow (risks and questions)” that government agencies have begun debating is independent media’s responsibility. “Patients have the right to know what they’re receiving and why medical history warns against it”—that’s all.
Summary
- ECM injectables are primarily manufactured from decellularized, powdered cadaver donor skin tissue as “5th generation” injectables. Rapidly expanding in Korea since 2024, with 7 products expected in Korean market by end-2026. In Japan, BNAJU (Elravie Re2O), Skinplus (CellREDM), JUVEACELL (ESSALIA), etc. introduced at select clinics
- Korea’s MFDS announced “regulation including legal amendments within H1 2026” on March 30, 2026—four issues officially confirmed: ①no clinical trials ②no SDS residue standards ③technical contradictions in decellularization ④deviation from donor purpose
- Consumer surveys show 60.9% support prohibition/strict regulation, ~70% express “aversion to cadaver-derived treatments” (Korea, multiple surveys)
- hADM-based ECM products introduced at select Japanese clinics. Known hADM-based ECM products (cadaver-derived) in Japanese market include BNAJU (Elravie Re2O), Skinplus (CellREDM), JUVEACELL (ESSALIA), etc. (noting these as examples of the category sharing structural issues discussed, not labeling them “problem products”). As Korean regulatory debates progress, discussions reviewing patient explanation protocols and product selection criteria are expected to intensify in Japan
Frequently Asked Questions
Important clarification first: Current ECM products use “skin tissue” as source material, anatomically different from “brain/pituitary tissue” that caused past tragedies. Therefore, equivalent prion infection risk is not immediately recognized.
However, the medical background to understand: In the 1960s–80s, growth hormone made from cadaver brain tissue became prion-contaminated, causing 226+ deaths worldwide (CDC, peer-reviewed journals confirm). Because prions cannot be completely inactivated by standard sterilization or chemical treatment, the medical community maintains extremely cautious attitudes toward “cadaver tissue injection” based on this historical lesson. While prion risk from ECM product skin tissue is considered substantially lower than brain tissue, sufficient evidence that “decellularization eliminates all pathogen risks” also doesn’t currently exist.
Sources: Edaily “ECM skin booster not medical device but human tissue…MFDS announces regulation” March 30, 2026 / Health Kyunghyang “Is my skin a guinea pig?…ECM skin booster controversy” May 27, 2026 / Cheongnyon Uisa (Korean Young Physicians Journal) “Donated human tissue for aesthetic procedures—is this acceptable?” April 27, 2026 / The Korea Herald “Skin boosters made from cadavers raise ethical concerns” April 17, 2026 / Medical Times “Not cadaver skin but regenerative technology—L&C Bio directly refutes Re2O controversy” April 29, 2026 / CDC Emerging Infectious Diseases “Cadaveric Human Growth Hormone–Associated Creutzfeldt-Jakob Disease with Long Latency Period” May 2025 (DOI:10.3201/eid3106.241519) / CIDRAP “Woman dies of Creutzfeldt-Jakob almost 50 years after taking prion-contaminated growth hormone” May 2025 / Appleby BS et al. “Iatrogenic CJD from Commercial Cadaveric hGH” Emerg Infect Dis 2013;19(4) / Dr Rachel Ho “ECM Skin Booster Controversies” May 2026
